Skip to main content
logo
Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · Real-Time Price · USD
4.760
+0.750 (18.70%)
At close: Nov 6, 2026, 4:00 PM EST
4.750
-0.010 (-0.21%)
After-hours: Nov 6, 2026, 4:10 PM EST

Gyre Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
110.06116.59105.76113.45102.29
Revenue Growth
-8.95%10.24%-6.78%10.91%-
Gross Profit
102.93111.17101.87108.8197.5
Operating Income
-18.2311.4916.2319.219.2
Net Income
-24.995.0312.09-92.932.3
Earnings Per Share
-0.260.020.05-1.410.03
EPS Growth
--53.23%---

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
70.0452.4326.6733.5125.18
Total Debt
3.010.941.60.410.61
Net Cash (Debt)
67.0351.4925.0733.124.56
Net Cash Growth
13.84%105.34%-24.25%34.76%-
Net Cash Per Share
0.690.500.250.500.32

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-6.341.01-3.6425.8910.68
Capital Expenditures
-1.41-1.19-2.32-8.52-4.99
Free Cash Flow
-7.75-0.18-5.9617.385.69
Free Cash Flow Growth
---205.25%-

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
93.53%95.36%96.33%95.91%95.31%
Operating Margin
-16.56%9.86%15.35%16.93%9.00%
Pretax Margin
-20.48%12.38%21.95%-67.84%9.20%
Profit Margin
-22.70%4.31%11.43%-81.92%2.25%
FCF Margin
-7.04%-0.15%-5.63%15.32%5.56%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22
PE Ratio
-127.6585.93--
Forward PE
-32.84---
P/FCF Ratio
---113.23-
PS Ratio
4.735.509.8217.34-